Skip to main content
    C

    Celldex Therapeutics Inc (CLDX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $28.59
    -0.24 (-0.83%)

    Market Cap: $2.26B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Celldex Therapeutics Inc (CLDX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Celldex Therapeutics reported revenue of $1.54M for the fiscal year ended Dec 31, 2025, down 78.0% from the year before. That year, net income was -$258.76M with a net margin of -16748.0%, operating cash flow was -$210.94M and free cash flow was -$213.66M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$75.56M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue fell from $6.79M, a compound annual decline of 15.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$1.54M-78.0%100.0%-18599.8%-16748.0%
    Dec 2024$7.02M+2.0%100.0%-2778.9%-2248.8%
    Dec 2023$6.88M+192.0%100.0%-2245.3%-2054.8%
    Dec 2022$2.36M-49.3%100.0%-4889.0%-4765.6%
    Dec 2021$4.65M-37.3%100.0%-1531.8%-1516.0%
    Dec 2020$7.42M+107.6%100.0%-854.1%-805.9%
    Dec 2019$3.57M-62.5%100.0%-1540.2%-1424.0%
    Dec 2018$9.54M-25.2%100.0%-1640.1%-1585.1%
    Dec 2017$12.74M+87.8%100.0%-953.7%-730.1%
    Dec 2016$6.79MN/A100.0%-1958.7%-1894.0%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$1.54M$7.02M$6.88M$2.36M$4.65M$7.42M$3.57M$9.54M$12.74M$6.79M
    Gross profit$1.54M$7.02M$6.88M$2.36M$4.65M$7.42M$3.57M$9.54M$12.74M$6.79M
    Research and development$245.07M$163.55M$118.01M$82.26M$53.31M$42.53M$42.67M$66.45M$96.17M$102.73M
    Operating income-$287.37M-$195.08M-$154.54M-$115.23M-$71.24M-$63.35M-$55.03M-$156.44M-$121.53M-$132.92M
    Net income-$258.76M-$157.86M-$141.43M-$112.33M-$70.51M-$59.78M-$50.88M-$151.18M-$93.03M-$128.53M
    EBITDAN/AN/AN/A-$111.49MN/A-$60.15M-$51.31M-$153.68M-$115.93M-$126.26M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$22.00K$15.00K$120.00K$0$730.00K$695.00K$1.18M$3.19M$2.50M$156.00K$4.13M
    Gross profit$0$22.00K$15.00K$120.00K$0$730.00K$695.00K$1.18M$3.19M$2.50M$156.00K$4.13M
    Operating income-$82.25M-$80.62M-$84.44M-$87.15M-$73.62M-$63.86M-$62.74M-$56.03M-$52.13M-$46.32M-$40.61M-$47.63M
    Net income-$75.56M-$73.50M-$78.69M-$81.32M-$67.04M-$56.60M-$53.80M-$47.09M-$42.12M-$35.84M-$32.81M-$43.31M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.55M by $27.32M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$582.98M$792.34M$465.63M$352.74M$444.65M$235.84M$122.93M$155.81M$315.62M$383.36M
    Current assets$534.66M$747.16M$431.69M$317.69M$410.84M$197.84M$66.70M$99.08M$144.76M$195.57M
    Cash and equivalents$28.87M$28.36M$34.81M$29.43M$39.14M$43.84M$11.23M$24.31M$40.29M$42.46M
    Total liabilities$55.82M$45.34M$36.46M$26.53M$25.18M$26.48M$28.91M$31.75M$79.25M$117.93M
    Short-term debt$1.55M$1.45M$1.61M$1.45M$1.75M$1.33M$3.89M$4.53M$6.57M$4.83M
    Shareholder equity$527.16M$747.00M$429.17M$326.20M$419.48M$209.36M$94.03M$124.06M$236.37M$265.43M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$721.53M$782.35M$511.25M$582.98M$648.44M$692.41M$739.47M$792.34M$823.18M$845.59M$868.85M$465.63M
    Total liabilities$72.06M$67.78M$55.03M$55.82M$50.08M$37.00M$36.49M$45.34M$37.27M$31.93M$30.23M$36.46M
    Cash and equivalents$26.95M$47.45M$35.73M$28.87M$36.04M$23.04M$17.14M$28.36M$36.40M$42.74M$115.08M$34.81M
    Shareholder equity$649.47M$714.56M$456.23M$527.16M$598.36M$655.41M$702.98M$747.00M$785.90M$813.66M$838.61M$429.17M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$210.94M-$157.78M-$107.29M-$103.73M-$60.91M-$40.40M-$46.41M-$75.23M-$99.93M-$113.04M
    Capital expenditures$2.71M$1.92M$1.82M$1.83M$1.25M$1.55M$731.00K$813.00K$1.79M$2.75M
    Free cash flow-$213.66M-$159.70M-$109.11M-$105.56M-$62.16M-$41.96M-$47.15M-$76.05M-$101.72M-$115.79M
    Investing cash flow$209.07M-$290.13M-$105.78M$89.94M-$216.16M-$98.22M$17.08M$29.82M$46.47M$68.91M
    Financing cash flow$2.39M$441.45M$218.46M$4.08M$272.37M$171.23M$16.26M$29.44M$51.29M$14.48M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$65.03M-$57.41M-$65.59M-$63.94M-$48.63M-$44.01M-$54.37M-$32.48M-$55.34M-$29.33M-$40.64M-$32.53M
    Capital expenditures$1.67M$3.18M$1.64M$1.28M$440.00K$728.00K$265.00K$756.00K$545.00K$274.00K$344.00K$666.00K
    Free cash flow-$66.70M-$60.59M-$67.23M-$65.22M-$49.07M-$44.73M-$54.64M-$33.23M-$55.88M-$29.60M-$40.98M-$33.20M
    Last 12 quarters

    Frequently Asked Questions About CLDX

    What is Celldex Therapeutics' annual revenue?

    Celldex Therapeutics reported revenue of $1.54M for the fiscal year ended Dec 31, 2025.

    How fast is Celldex Therapeutics' revenue growing?

    Revenue was down 78.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -13.1%.

    Is Celldex Therapeutics profitable?

    No. Celldex Therapeutics reported net income of -$258.76M for the fiscal year ended Dec 31, 2025, with a net margin of -16748.0%.

    How much free cash flow does CLDX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$210.94M minus capital expenditures of $2.71M produced free cash flow of -$213.66M.

    How much debt does Celldex Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.55M and cash and equivalents of $28.87M.